Project Description

Work group 1

WG1 concentrates on the biomedical aspects of multiscale systems medicine, informed by clinical research and medical practice in various broad disease areas, including various types of cancer, respiratory, neuro, immune and cardiovascular diseases, as well as research on ageing and environmental effects on health. The main goals of WG1 are
(1) To identify health/disease areas where a multiscale systems medicine approach is likely to lead to improved outcomes (disease understanding, prevention, diagnosis, treatment, prognosis) over established approaches.
(2) To define and evaluate concrete requirements informing the development of novel ICT multiscale methods and tools needed to address the challenges of a multiscale approach to systems medicine.
(3) To identify clinical and non-clinical (e.g. toxicity, environment, lifestyle) data sets that capture information relevant to multiscale modelling, analysis and simulation approach.
(4) To demonstrate and evaluate the medical and economic effectiveness of a multiscale systems medicine in promoting health, preventing disease, and reducing the disease burden (mortality, morbidity, financial cost).

Clinical drivers informing the activities in WG1 include

Predictive, preventive, personalized and participatory medicine (P4 medicine)

Pharmaceutical drug and vaccine development, production, delivery and safety combined with patient stratification approaches

Discovery of effective diagnostics biomarkers and their multi-dimensional combination

Linking multiscale data signatures to disease processes

Methods to predict treatment response and disease progression in a given patient

Rational design of combinatorial therapies (e.g. dosing)

Reduction of healthcare costs through systems-based prevention; patient stratification;
tailored therapies; disease management and telemedicine (e-health) approaches.